Friday, September 25, 2020

Onconova Therapeutics Inc. [ONTX] Revenue clocked in at $0.20 million, down -42.66% YTD: What’s Next?

Must read

First Analysis Sec slashes price target on CryoLife Inc. [CRY] – find out why.

CryoLife Inc. jumped around 0.64 points on Friday, while shares priced at $17.38 at the close of the session, up 3.82%. The company...

Market Analysts see Camping World Holdings Inc. [CWH] gaining to $40. Time to buy?

Camping World Holdings Inc. traded at a low on 09/24/20, posting a -3.18 loss after which it closed the day’ session at $28.27....

A. O. Smith Corporation [AOS] Is Currently 2.76 below its 200 Period Moving Avg: What Dose This Mean?

A. O. Smith Corporation gained 2.76% or 1.43 points to close at $53.18 with a heavy trading volume of 1945005 shares. It opened...

JFrog Ltd. [FROG] Revenue clocked in at $127.90 million, up 19.94% YTD: What’s Next?

JFrog Ltd. gained 15.99% or 10.71 points to close at $77.71 with a heavy trading volume of 4106219 shares. If we look at...

Onconova Therapeutics Inc. [NASDAQ: ONTX] price plunged by -8.77 percent to reach at -$0.02.

A sum of 23492558 shares traded at recent session while its average daily volume was at 19.47M shares. Onconova Therapeutics Inc. shares reached a high of $0.225 and dropped to a low of $0.2101 until finishing in the latest session at $0.22.

The average equity rating for ONTX stock is currently 3.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Onconova Therapeutics Inc. [ONTX]:

H.C. Wainwright have made an estimate for Onconova Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 01, 2018. The new note on the price target was released on January 17, 2018, representing the official price target for Onconova Therapeutics Inc. stock. Previously, the target price had yet another raise to $6, while H.C. Wainwright analysts kept a Buy rating on ONTX stock.

The Average True Range (ATR) for Onconova Therapeutics Inc. is set at 0.12, with the Price to Sales ratio for ONTX stock in the period of the last 12 months amounting to 206.38. The Price to Book ratio for the last quarter was 2.44, with the Price to Cash per share for the same quarter was set at 0.14.

ONTX Stock Performance Analysis:

Onconova Therapeutics Inc. [ONTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.56. With this latest performance, ONTX shares dropped by -80.74% in over the last four-week period, additionally sinking by -55.68% over the last 6 months – not to mention a drop of -90.45% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ONTX stock in for the last two-week period is set at 24.47, with the RSI for the last a single of trading hit 13.97, and the three-weeks RSI is set at 29.25 for Onconova Therapeutics Inc. [ONTX]. The present Moving Average for the last 50 days of trading for this stock 0.8081, while it was recorded at 0.2615 for the last single week of trading, and 0.4887 for the last 200 days.

Insight into Onconova Therapeutics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Onconova Therapeutics Inc. [ONTX] shares currently have an operating margin of -994.00. Onconova Therapeutics Inc.’s Net Margin is presently recorded at -985.02.

Return on Total Capital for ONTX is now -255.87, given the latest momentum, and Return on Invested Capital for the company is -253.56. Return on Equity for this stock declined to -253.56, with Return on Assets sitting at -103.39.

Reflecting on the efficiency of the workforce at the company, Onconova Therapeutics Inc. [ONTX] managed to generate an average of -$1,131,737 per employee. Receivables Turnover for the company is 32.83 with a Total Asset Turnover recorded at a value of 0.10.Onconova Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.


With the latest financial reports released by the company, Onconova Therapeutics Inc. posted -0.75/share EPS, while the average EPS was predicted by analysts to be reported at -0.56/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -33.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ONTX.

Onconova Therapeutics Inc. [ONTX] Insider Position Details

There are presently around $2 million, or 9.70% of ONTX stock, in the hands of institutional investors. The top three institutional holders of ONTX stocks are: VANGUARD GROUP INC with ownership of 6,101,122, which is approximately 164.992% of the company’s market cap and around 0.20% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 1,187,400 shares of the stock with an approximate value of $0.26 million in ONTX stocks shares; and BLACKROCK INC., currently with $0.19 million in ONTX stock with ownership of nearly 1.887% of the company’s market capitalization.

Positions in Onconova Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 21 institutional holders increased their position in Onconova Therapeutics Inc. [NASDAQ:ONTX] by around 6,204,783 shares. Additionally, 7 investors decreased positions by around 1,928,592 shares, while 9 investors held positions by with 2,407,138 shares. The mentioned changes placed institutional holdings at 10,540,513 shares, according to the latest SEC report filing. ONTX stock had 14 new institutional investments in for a total of 2,190,943 shares, while 5 institutional investors sold positions of 841,720 shares during the same period.

More articles


Please enter your comment!
Please enter your name here

Latest article

Summit Midstream Partners LP [SMLP] Is Currently 8.14 above its 200 Period Moving Avg: What Dose This Mean?

Summit Midstream Partners LP price surged by 8.14 percent to reach at $0.06. A sum of 1052688 shares traded at recent session while...

Precision BioSciences Inc. [DTIL] moved up 12.92: Why It’s Important

Precision BioSciences Inc. gained 12.92% or 0.68 points to close at $5.90 with a heavy trading volume of 2920862 shares. It opened the...

Fortress Value Acquisition Corp. [FVAC] Stock trading around $13.89 per share: What’s Next?

Fortress Value Acquisition Corp. closed the trading session at $13.89 on 09/24/20. The day’s price range saw the stock hit a low of...

Callon Petroleum Company [CPE] fell -89.13% so far this year. What now?

Callon Petroleum Company jumped around 0.22 points on Thursday, while shares priced at $5.25 at the close of the session, up 4.37%. Callon...

Market cap of Aehr Test Systems [AEHR] reaches 33.56M – now what?

Aehr Test Systems stock went on a downward path that fall over -0.69% on Thursday, amounting to a one-week price decrease of less...